Immune Design Corp. (NASDAQ:IMDZ) saw strong trading volume on Monday . 164,703 shares were traded during trading, an increase of 63% from the previous session’s volume of 101,032 shares.The stock last traded at $6.82 and had previously closed at $6.57.

A number of research analysts have weighed in on the company. Zacks Investment Research downgraded Immune Design Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th. Leerink Swann reiterated a “buy” rating on shares of Immune Design Corp. in a report on Friday, June 10th. Finally, Jefferies Group reiterated a “buy” rating and set a $17.00 target price (down previously from $20.00) on shares of Immune Design Corp. in a report on Wednesday, August 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $14.50.

The company’s market cap is $143.24 million. The company has a 50 day moving average price of $7.07 and a 200 day moving average price of $10.26.

Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by $0.03. Immune Design Corp. had a negative net margin of 525.30% and a negative return on equity of 44.57%. Equities analysts predict that Immune Design Corp. will post ($2.70) earnings per share for the current year.

In other Immune Design Corp. news, Director Lewis W. Coleman purchased 40,000 shares of the stock in a transaction that occurred on Tuesday, September 20th. The stock was purchased at an average price of $6.25 per share, with a total value of $250,000.00. Following the acquisition, the director now owns 50,000 shares in the company, valued at $312,500. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 42.90% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in IMDZ. Highbridge Capital Management LLC acquired a new position in shares of Immune Design Corp. during the second quarter worth approximately $215,000. Panagora Asset Management Inc. increased its stake in shares of Immune Design Corp. by 8.0% in the second quarter. Panagora Asset Management Inc. now owns 96,644 shares of the company’s stock valued at $789,000 after buying an additional 7,190 shares during the last quarter. State Street Corp increased its stake in shares of Immune Design Corp. by 23.5% in the second quarter. State Street Corp now owns 207,670 shares of the company’s stock valued at $1,694,000 after buying an additional 39,551 shares during the last quarter. Spark Investment Management LLC increased its stake in shares of Immune Design Corp. by 110.0% in the second quarter. Spark Investment Management LLC now owns 77,500 shares of the company’s stock valued at $632,000 after buying an additional 40,600 shares during the last quarter. Finally, Pictet Asset Management Ltd. increased its stake in shares of Immune Design Corp. by 768.9% in the second quarter. Pictet Asset Management Ltd. now owns 748,145 shares of the company’s stock valued at $9,389,000 after buying an additional 662,045 shares during the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

5 Day Chart for NASDAQ:IMDZ

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.